This study is in progress, not accepting new patients
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Bartosz Chmielowski
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Bartosz Chmielowski
HS Clinical Professor, Medicine. Authored (or co-authored) 129 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- RAPT Therapeutics, Inc.
- ID
- NCT03674567
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 323 people participating
- Last Updated